1. Home
  2. ATHA vs GNLN Comparison

ATHA vs GNLN Comparison

Compare ATHA & GNLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATHA
  • GNLN
  • Stock Information
  • Founded
  • ATHA 2011
  • GNLN 2005
  • Country
  • ATHA United States
  • GNLN United States
  • Employees
  • ATHA N/A
  • GNLN N/A
  • Industry
  • ATHA Medicinal Chemicals and Botanical Products
  • GNLN Durable Goods
  • Sector
  • ATHA Health Care
  • GNLN Consumer Discretionary
  • Exchange
  • ATHA Nasdaq
  • GNLN Nasdaq
  • Market Cap
  • ATHA 14.8M
  • GNLN 12.9M
  • IPO Year
  • ATHA 2020
  • GNLN 2019
  • Fundamental
  • Price
  • ATHA $0.36
  • GNLN $3.77
  • Analyst Decision
  • ATHA Hold
  • GNLN
  • Analyst Count
  • ATHA 3
  • GNLN 0
  • Target Price
  • ATHA $0.50
  • GNLN N/A
  • AVG Volume (30 Days)
  • ATHA 149.8K
  • GNLN 78.8K
  • Earning Date
  • ATHA 11-06-2025
  • GNLN 08-14-2025
  • Dividend Yield
  • ATHA N/A
  • GNLN N/A
  • EPS Growth
  • ATHA N/A
  • GNLN N/A
  • EPS
  • ATHA N/A
  • GNLN N/A
  • Revenue
  • ATHA N/A
  • GNLN $7,954,000.00
  • Revenue This Year
  • ATHA N/A
  • GNLN $1,541.21
  • Revenue Next Year
  • ATHA N/A
  • GNLN N/A
  • P/E Ratio
  • ATHA N/A
  • GNLN N/A
  • Revenue Growth
  • ATHA N/A
  • GNLN N/A
  • 52 Week Low
  • ATHA $0.22
  • GNLN $2.84
  • 52 Week High
  • ATHA $0.83
  • GNLN $5,944.50
  • Technical
  • Relative Strength Index (RSI)
  • ATHA 36.59
  • GNLN 52.19
  • Support Level
  • ATHA $0.35
  • GNLN $3.15
  • Resistance Level
  • ATHA $0.40
  • GNLN $3.41
  • Average True Range (ATR)
  • ATHA 0.02
  • GNLN 0.26
  • MACD
  • ATHA -0.00
  • GNLN 0.13
  • Stochastic Oscillator
  • ATHA 11.86
  • GNLN 82.68

About ATHA Athira Pharma Inc.

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.

About GNLN Greenlane Holdings Inc.

Greenlane Holdings Inc is a platform for the development and distribution of premium cannabis accessories, vape devices, and lifestyle products. It provides a wide array of consumer ancillary products and industrial ancillary products to thousands of cannabis producers, processors, brands, and retailers (Cannabis Operators). In addition, it serves specialty retailers, smoke shops, head shops, convenience stores, and consumers directly through its proprietary web stores and large online marketplaces such as Amazon. Its geographical segment includes the United States, Canada, and Europe. It derives a majority of revenue from the United States.

Share on Social Networks: